Cart
sales@molnova.com
Diclofensine hydrochloride
CAS No. 34041-84-4
Diclofensine hydrochloride( Ro 8-4650 hydrochloride )
Catalog No. M20950 CAS No. 34041-84-4
Diclofensine hydrochloride is a Novel Antidepressant on Peripheral Adrenergic Function.
Purity : >98% (HPLC)
COA
Datasheet
HNMR
HPLC
MSDS
Handing Instructions
| Size | Price / USD | Stock | Quantity |
| 5MG | 42 | Get Quote |
|
| 10MG | 69 | Get Quote |
|
| 25MG | 140 | Get Quote |
|
| 50MG | 267 | Get Quote |
|
| 100MG | 385 | Get Quote |
|
| 200MG | 538 | Get Quote |
|
| 500MG | Get Quote | Get Quote |
|
| 1G | Get Quote | Get Quote |
|
Biological Information
-
Product NameDiclofensine hydrochloride
-
NoteResearch use only, not for human use.
-
Brief DescriptionDiclofensine hydrochloride is a Novel Antidepressant on Peripheral Adrenergic Function.
-
DescriptionDiclofensine hydrochloride is a Novel Antidepressant on Peripheral Adrenergic Function.
-
In Vitro——
-
In Vivo——
-
SynonymsRo 8-4650 hydrochloride
-
PathwayOthers
-
TargetOther Targets
-
RecptorOthers
-
Research Area——
-
Indication——
Chemical Information
-
CAS Number34041-84-4
-
Formula Weight358.69
-
Molecular FormulaC17H18Cl3NO
-
Purity>98% (HPLC)
-
SolubilityH2O:52 mg/mL (144.97 mM)
-
SMILESCOc1ccc2c(c1)CN(C)CC2c1ccc(Cl)c(Cl)c1.Cl
-
Chemical Name4-(34-Dichlorophenyl)-7-methoxy-2-methyl-34-dihydro-1H-isoquinoline hydrochloride
Shipping & Storage Information
-
Storage(-20℃)
-
ShippingWith Ice Pack
-
Stability≥ 2 years
Reference
1.S Gasi? Korn A Eichler H G . Effect of diclofensine a novel antidepressant on peripheral adrenergic function[J]. Clinical Pharmacology & Therapeutics 1986 39.
molnova catalog
related products
-
RS-127445
RS-127445 is a selective 5-HT2B receptor antagonist with pKi of 9.5 and pIC50 of 10.4, exhibits >1000-fold selectivity against other 5-HT receptors.
-
Rhamnetin
Rhamnetin, a quercetin derivative found in Coriandrum sativum, has antioxidant and anti-inflammatory activities. Rhamnetin inhibits secretory phospholipase A2.
-
MBC-11
MBC-11 is a first-in-class conjugate of the bone-targeting bisphosphonate etidronate covalently linked to the antimetabolite cytarabine (araC), with potential to treat tumor-induced bone disease (TIBD).
